licensing

News

Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.

News

Spero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R&D.

News

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5bn licensing deal for Dizal Pharma's lung cancer therapy Zegfrovy.

News

AstraZeneca has licensed a drug candidate for COPD from China's Sino Bio, which could compete with MSD's Ohtuvayre, in a deal valued at up to $2.1bn.

R&D

Although eCOA has been in clinical trials for decades, we continue to hit the same road blocks during operational set-up and implementation.

News

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.